Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity.

Antisense Res Dev. 1991 Summer;1(2):173-86. Unique Identifier : AIDSLINE MED/93044231
Taylor NR; Rossi JJ; Department of Molecular Genetics, Beckman Research Institute of; the City of Hope, Duarte, CA 91010.

Abstract: Catalytic antisense RNAs, or ribozymes, have great potential as inhibitors of gene expression and as antiviral therapeutic agents. The major advantage of ribozymes versus standard antisense RNAs is their catalytic capability, enabling these RNAs to cleave multiple substrates. We have been investigating the antiviral activity of ribozymes targeted to the HIV-1 genome. The successful use of these antisense agents in an intracellular milieu requires stabilization of the ribozymes by flanking, non-base-pairing sequences, or some modification of the sugar-phosphate backbone. We describe a systematic investigation of the effects of flanking, non-base-pairing sequences on the catalytic activity of an anti-HIV-1 gag ribozyme embedded in radically different transcripts. Amazingly, these complex ribozyme-containing transcripts maintain substantial catalytic activity. Finally, we describe a bacterial gene fusion system that has potential for the large scale production of catalytically active ribozymes.
Keywords: Base Sequence Cloning, Molecular Comparative Study Escherichia coli/GENETICS *Genes, gag Genes, Bacterial Genome, Viral HIV-1/*GENETICS/METABOLISM Kinetics Molecular Sequence Data Nucleic Acid Conformation Plasmids Restriction Mapping RNA, Bacterial/GENETICS/METABOLISM RNA, Catalytic/GENETICS/*METABOLISM RNA, Viral/*METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Thermodynamics JOURNAL ARTICLEKWDbasesequencecloning,molecularcomparativestudyescherichiacoli/geneticsKWDgenes,gaggenes,bacterialgenome,viralhiv-1/KWDgenetics/metabolismkineticsmolecularsequencedatanucleicacidconformationplasmidsrestrictionmappingrna,bacterial/genetics/metabolismrna,catalytic/genetics/KWDmetabolismrna,viral/KWDmetabolismsupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDthermodynamicsjournalarticle
930228
M9320847

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .